From: Effect of long-term adjuvant temozolomide chemotherapy on primary glioblastoma patient survival
Patient number | PFS | P | OS | P | |
---|---|---|---|---|---|
HR | HR | ||||
(95%CI) | (95%CI) | ||||
MGMT methylation | |||||
No | 23 | 1 | 1 | ||
Yes | 26 | 0.336 | 0.002 | 0.470 | 0.025 |
(0.167–0.674) | (0.243–0.909) | ||||
IDH | |||||
Wild type | 29 | 1 | 1 | ||
Mutation | 10 | 0.094 | 0.077 | ||
(0.026–0.346) | < 0.001 | (0.016–0.384) | 0.002 | ||
TMZ therapeutic cycles | |||||
6 | 27 | 1 | – | ||
> 6 | 26 | 0.224 | < 0.001 | – | |
(0.106–0.473) | |||||
Brain lobes involved in tumor | |||||
Single lobe | 34 | 1 | |||
Multiple lobes | 19 | 0.406 | 0.012 | – | |
(0.201–0.819) | |||||
Pre-surgery KPS score | |||||
< 80 | 11 | – | 1 | ||
> 80 | 42 | – | 0.192 | < 0.001 | |
(0.079–0.464) |